Trials / Recruiting
RecruitingNCT06082050
Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 7 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, open-label, single-dose escalation trial aimed at evaluating the safety and tolerability of YOLT-201 treatment in patients with Transthyretin Amyloidosis Cardiomyopathy （ATTR-CM）, as well as assessing the preliminary efficacy of subjects treated with YOLT-201.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YOLT-201 | Infusion of YOLT-201 at Day 1， Subjects may voluntarily accept the second study drug treatment at the OBD (Optimal Biological Dose) level. |
Timeline
- Start date
- 2023-11-02
- Primary completion
- 2025-07-03
- Completion
- 2026-02-10
- First posted
- 2023-10-13
- Last updated
- 2025-02-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06082050. Inclusion in this directory is not an endorsement.